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Abstract
Background: To assess the incidence of venous thromboembolism (VTE) and bleeding events with or without
thromboprophylaxis and the associated costs in a cohort of medically ill patients in both in-hospital and outpatient
settings.
Methods: A large hospital drug database and linked outpatient files were used to identify patients eligible for this
analysis, based on demographic and clinical characteristics.
Results: Among 11,135 patients identified, 1592 (14.30%) were admitted with chronic heart failure, 1684 (15.12%)
with thromboembolic stroke, 3834 (34.43%) with severe lung disease, 1658 (14.89%) with acute infection, and 2367
(21.26%) with cancer. Of the 11,135 patients, 5932 received anticoagulant therapy at some point during their
hospitalization and until 30 days after discharge. VTE events occurred in 1.30% of patients who received
anticoagulant prophylaxis versus 2.99% of patients who did not. Risk-adjusted total healthcare costs for patients
with a VTE or major or minor bleeding event were significantly higher than for those without events (VTE: $52,157
± 24,389 vs $24,164 ± 11,418; major bleeding: $33,656 ± 18,196 vs $24,765 ± 11,974; minor bleeding: $33,690 ±
14,398 vs $23,610 ± 11,873). In a multivariate analysis, appropriate anticoagulant prophylaxis use was significantly
associated with a reduced risk of clinical VTE, compared with no anticoagulant use (hazard ratio: 0.37). Patients
admitted with thromboembolic stroke were less likely to have a VTE than patients admitted with cancer (hazard
ratio: 0.42).
Conclusions: In this analysis, VTE and major bleeding event rates were lower for patients who received prophylaxis
compared with those who did not. Prophylaxis use was associated with lower healthcare costs.
Background
Venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), is an
important cause of disability and death. Many patients
require hospitalization, and the annual death rate from
VTE is estimated to be as high as 300,000 persons per
year [1]. Various medical diseases confer a high risk of
VTE, including malignant neoplasms, with and without
chemotherapy; prior superficial vein thrombosis; and
neurological diseases with extremity paresis [2]. Among
hospitalized non-surgical patients, VTE risk is especially
high in those who are critically ill. Moderate to high risk
of VTE has been documented in patients with acute
myocardial infarction (MI; 24%) and in the paretic or
paralyzed lower extremity of ischemic stroke patients
(55%) [3].
The American College of Chest Physicians (ACCP)
guidelines on antithrombotic therapy recommend the
use of pharmacologic thromboprophylaxis in hospitalized
medical patients at significant risk of VTE [3,4]. How-
ever, despite these guidelines, VTE prophylaxis is under-
utilized for medical non-surgical patients compared with
surgical patients [4-6].
While results of randomized trials or prospective obser-
vational studies could determine the benefits of VTE pro-
phylaxis in hospitalized medically ill patients, this
approach would be both expensive and time consuming.
Moreover, in areas such as VTE prophylaxis, real-world
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methodologies. The present analysis attempts to address
this problem. We have used an electronic hospital drug
database with linked outpatient data to specifically investi-
gate the use of thromboprophylaxis and rates of outcomes
events such as VTE, major bleeding, minor bleeding, and
costs among medically ill patients, both during hospitaliza-
tion and post-discharge.
Methods
Data Sources and Study Population
This analysis used a subset of the MarketScan
® databases
and linked outpatient files from the Market Scan Com-
mercial and Medicare Supplemental databases from
Thomson Reuters.T h eMarket Scan Commercial and
Market Scan Medicare Supplemental databases [7] include
submitted claims (UB02 format) linked to detailed service-
level hospital bills for the same admissions. By 2007, data
for nearly 22,189 patient-level hospital records had been
successfully linked to longitudinal claims histories in the
Market Scan Commercial and Market Scan Medicare Sup-
plemental databases. The linkage was conducted for 172
hospitals identifiable in both the hospital and claims data-
bases. The data include full census annual admissions for
each contributing hospital. Claims data are fully adjudi-
cated and paid claims from covered medical and pharmacy
services are from geographically dispersed private and
public health plans [8].
For our analysis, the following patient-level identifiers
were used to match the claims and inpatient databases:
admission date, discharge date, age, sex, and principal
diagnosis; cases that were uniquely characterized by these
variables were identified. The paid claims were linked with
a record that matched the same combination of these vari-
ables. This match was considered to be the same patient,
given that each combination of matching variables was
unique within the hospital census [9].
For this analysis, data from commercial and Medicare
patients, between January 1, 2005, and December 31,
2007, with a first principal medical diagnosis that fell into
the acute medical illness category were considered for
inclusion. Categories included: (1) chronic heart failure,
(2) thromboembolic stroke, (3) severe lung disease, (4)
acute infection, and (5) cancer. (See Appendix for ICD-9-
CM codes used to identify medical conditions.) For inclu-
sion, all patients must have had continuous enrollment in
their health plans for ≥180 days prior to and 180 days fol-
lowing the date of admission, which was defined as the
index date.
Demographic (age, gender, geographic location) and
clinical characteristics were derived from the claims data-
base. The Deyo adaptation of the Charlson Comorbidity
Index [10-12] was used to calculate relative baseline
comorbidities for each patient. Presence of hypertension,
renal disease, and cancer (excluding myelodysplastic syn-
drome) during the baseline period were also identified,
and baseline characteristics were compared among the
patient cohorts. Descriptive statistics were calculated as
means ± standard deviation (SD) and percentages. Differ-
ences between the cohorts were analyzed using the t-test,
Mann-Whitney U test, and chi-square test.
The timing of use of any guideline-recommended antic-
oagulant–low molecular weight heparin (LMWH), war-
farin, unfractionated heparin (UFH), or fondaparinux–was
measured from the index date until 180 days after hospital
discharge. In order to determine whether prophylaxis use
was appropriate according to published guidelines [4],
patients had to have received any anticoagulant after the
index date and within 30 days of hospital discharge and
before the date of their first clinical VTE.
Patients who developed clinical VTE were identified on
the basis of: (1) a primary or secondary diagnosis for DVT
(ICD-9-CM 451.1x-451.81, 451.83-451.9x or 452.xx or
453.2-453.9x) or PE (ICD-9-CM: 415.1x) on the medical
claim between the index date and 180 days after hospital
discharge, and (2) receipt of an anticoagulant drug within
15 days of the date of this claim.
All outcomes were assessed 180 days from the index
hospitalization. In addition to the incidence of VTE events,
the incidence of major and minor bleeding was also
assessed, using the appropriate ICD-9-CM codes. The
median time to all outcome events was estimated using
the Cox proportional hazard regression model. Costs for
180 days post-discharge were calculated to compare
patients in the no-prophylaxis cohort with patients in the
any-anticoagulant prophylaxis cohort.
Logistic regression fits models of the rate of event were
used to estimate risk-adjusted event rates within 180 days
of discharge. A generalized linear model with a log-link
function and gamma distribution was used to assess the
independent effects of covariates on total 180-day follow-
up costs. Statistical analyses were performed using SAS
®
v9.2 and STATA
® v10 software.
Results
A total of 11,135 patients from the linked database met
the inclusion criteria for medical patients at risk of VTE.
The most-common medical diagnosis was severe lung dis-
ease (34.43%), followed by cancer (21.26%), thromboem-
bolic stroke (15.12%), acute infection (14.89%), and
chronic heart disease (14.30%). The average age of patients
was 66 years; 47.8% were men and 52.2% women. Most
patients lived in the southern part of the United States.
During the 6-month baseline period, the most commonly
identified risk factors for VTE were hypertension (39.41%)
and diabetes (23.73%). VTE was diagnosed in 2.56% of
patients. The total outpatient cost at baseline was $17,815
per patient (Table 1). Of the eligible patients, only 5932
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Page 2 of 10Table 1 Demographic and clinical characteristics for medically ill patients*
Chronic heart failure
(N = 1592)
Thromboembolic stroke
(N = 1684)
Severe lung disease
(N = 3834)
Acute infection
(N = 1658)
Cancer
(N = 2367)
Total
(n = 11,135)
Mean, n SD, % Mean, n SD, % Mean, n SD, % Mean, n SD, % Mean, n SD, % Mean, N SD, %
Age, yr (mean) 71.13 12.97 70.67 12.06 64.04 20.20 63.59 20.01 63.48 13.20 65.87 17.14
Median 74 73 69 67 64 69
Max 99 97 101 100 99 101
Min 23 20 1 1 2 1
0-64 471 29.59% 523 31.06% 1596 41.63% 762 45.96% 1256 53.06% 4608 41.38%
65-74 378 23.74% 416 24.70% 880 22.95% 333 20.08% 604 25.52% 2611 23.45%
75-84 528 33.17% 562 33.37% 1034 26.97% 390 23.52% 424 17.91% 2938 26.39%
85-94 194 12.19% 174 10.33% 311 8.11% 160 9.65% 80 3.38% 919 8.25%
95+ 21 1.32% 9 0.53% 13 0.34% 13 0.78% 3 0.13% 59 0.53%
Gender (male) 892 56.03% 873 51.84% 1732 45.17% 738 44.51% 1092 46.13% 5327 47.84%
Region
Northeast 18 1.13% 13 0.77% 74 1.93% 26 1.57% 38 1.61% 169 1.52%
North Central 375 23.56% 358 21.26% 1035 27.00% 401 24.19% 380 16.05% 2549 22.89%
South 1184 74.37% 1291 76.66% 2677 69.82% 1214 73.22% 1920 81.12% 8286 74.41%
West 15 0.94% 22 1.31% 48 1.25% 17 1.03% 29 1.23% 131 1.18%
Comorbid Conditions (baseline)
Elixhauser Comorbidity Index ≥2% 213 13.38% 113 6.71% 343 8.95% 164 9.89% 355 15.00% 1188 10.67%
Charlson Comorbidity Index 1.99 1.85 1.40 1.49 1.46 1.71 1.46 1.92 2.81 2.52 1.81 2.01
Congestive heart failure 792 49.75% 122 7.24% 422 11.01% 183 11.04% 76 3.21% 1595 14.32%
Peripheral arterial disease 105 6.60% 149 8.85% 188 4.90% 91 5.49% 63 2.66% 596 5.35%
Acute coronary syndrome 140 8.79% 50 2.97% 101 2.63% 41 2.47% 37 1.56% 369 3.31%
Hyperthyroidism 12 0.75% 6 0.36% 19 0.50% 7 0.42% 23 0.97% 67 0.60%
Obesity 39 2.45% 18 1.07% 67 1.75% 53 3.20% 33 1.39% 210 1.89%
Diabetes 583 36.62% 422 25.06% 791 20.63% 459 27.68% 387 16.35% 2642 23.73%
Hypertension 747 46.92% 757 44.95% 1273 33.20% 654 39.45% 957 40.43% 4388 39.41%
Ischemic stroke 122 7.66% 680 40.38% 212 5.53% 90 5.43% 89 3.76% 1193 10.71%
Hemorrhagic stroke 4 0.25% 11 0.65% 7 0.18% 6 0.36% 4 0.17% 32 0.29%
Non-CNS systemic embolism 17 1.07% 8 0.48% 50 1.30% 41 2.47% 28 1.18% 144 1.29%
Transient ischemic attack 29 1.82% 170 10.10% 51 1.33% 23 1.39% 21 0.89% 294 2.64%
Catheter ablation 530 33.29% 233 13.84% 437 11.40% 226 13.63% 177 7.48% 1603 14.40%
Dyspepsia 7 0.44% 5 0.30% 17 0.44% 9 0.54% 19 0.80% 57 0.51%
Healthcare Cost (baseline), $USD
Outpatient ED $205 $531 $179 $546 $205 $650 $263 $790 $198 $1,780 $208 $999
Outpatient office visit $478 $427 $396 $351 $421 $524 $442 $508 $707 $618 $489 $522
Outpatient pharmacy $2,019 $2,021 $1,639 $1,909 $2,244 $2,851 $2,151 $2,770 $1,506 $2,610 $1,950 $2,572
Outpatient other $5,745 $16,318 $4,248 $11,027 $5,302 $15,744 $7,493 $20,180 $11,037 $18,891 $6,752 $16,853
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0Table 1 Demographic and clinical characteristics for medically ill patients* (Continued)
Total outpatient $8,447 $16,913 $6,462 $11,686 $8,172 $16,607 $10,350 $21,322 $13,448 $20,312 $9,398 $17,815
Baseline VTE 49 3.08% 21 1.25% 85 2.22% 73 4.40% 57 2.41% 285 2.56%
Admission Diagnosis
Chronic heart disease 1592 100.00% 1592 14.30%
Thromboembolic stroke 1684 100.00% 1684 15.12%
Severe lung disease 3834 100.00% 3834 34.43%
Acute infection 1658 100.00% 1658 14.89%
Cancer 2367 100.00% 2367 21.26%
CNS, central nervous system; ED, emergency department; SD, standard deviation; USD, US dollars; VTE, venous thromboembolism.
*6 months prior to admission is pre-period.
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0(53.2%) received the appropriate anticoagulant VTE pro-
phylaxis. The rate ranged from 69.3% in chronic heart fail-
ure to 46.3% in cancer patients (Table 2). In patients with
no appropriate anticoagulant prophylaxis, the rate of clini-
cal VTE over 180 days was 3.65%; however, clinical VTE
rates were much lower by 180 days (1.79%) in patients
with appropriate anticoagulant prophylaxis (Table 3).
A clear trend for occurrence of all-cause readmission
was observed in 12.99% of patients with no appropriate
prophylaxis and 18.83% of those with appropriate prophy-
laxis. The pattern of greater rehospitalization also existed
among patients in the any-anticoagulant prophylaxis
cohort.
Table 2 presents the risk-adjusted outcome results. The
cumulative rate of clinical VTE at 180 days was more
than two times higher for patients who did not use
appropriate anticoagulant prophylaxis compared with
those who did (2.99% vs 1.30%, p < 0.0001). Observed
rates of major and minor bleeding were similar in the
two cohorts.
Table 4 shows that 180-day follow-up costs were signifi-
cantly associated with outcome events. Of 11,135 patients
who had an acute medical illness diagnosed, 296 (2.66%)
had clinical VTE, 208 (1.87%) had major bleeding, and
1465 (13.16%) had minor bleeding by 180 days after index
hospital discharge. For patients with outcome events, risk-
adjusted total healthcare costs were significantly greater
than for those without events (VTE: $52,157 ± 24,389 vs
$24,164 ± 11,418, p < 0.0001; major bleeding: $33,656 ±
18,196 vs $24,765 ± 11,974, p < 0.0001; minor bleeding:
$33,690 ± 14,398 vs $23,610 ± 11,873, p < 0.0001).
In the multivariate Cox proportional hazard regression
model, two variables were significantly associated with a
reduced risk of clinical VTE: thromboembolic stroke
(hazard ratio [HR]: 0.42) and treatment with any anticoa-
gulant (HR: 0.37). The median time to clinical VTE for
patients receiving anticoagulant prophylaxis was 182 days,
whereas for patients without anticoagulant prophylaxis it
was only 27 days (p < 0.0001). When controlling for other
factors, two significant independent predictors of major
bleeding were found: more male patients than female
patients had major bleeding during the follow-up period
(HR: 1.42, p = 0.0162), and more patients in the western
region of the United States than those in the north central
region of the United States suffered major bleeding (HR:
0.30, p = 0.0493).
Different patterns were observed for patients with
minor bleeding. Fewer patients admitted with chronic
heart failure, thromboembolic stroke, or severe lung dis-
ease had minor bleeding relative to patients admitted
with cancer (HR: 0.79, 0.64, 0.80, respectively) (Table 5).
Table 6 presents the patient-day-based market share of
anticoagulant treatment for patients who have diagnoses
of acute medical illness. Among 11,135 patients, 3390
(30.44%) were treated with LMWH, 1629 (14.63%) with
warfarin, 3531 (31.71%) with UFH, and 42 (0.38%) with
fondaparinux within 180 days after index hospital dis-
charge. The median duration of therapy was 4 days for
LMWH and warfarin, 3 days for UFH, and 6 days for fon-
daparinux. Although warfarin was not administered to
the majority of medically ill patients, the total days of
warfarin use were the highest. Table 6 also demonstrates
Table 2 Anticoagulant prophylaxis use among medically ill patients*
Unadjusted percentage Risk-adjusted percentage
Outcome Appropriate prophylaxis, %
(n = 5932)
No prophylaxis, %
(n = 5203)
P-value Apppropriate prophylaxis, %
(n = 5932)
No prophylaxis, %
(n = 5203)
P-value
VTE 1.79 3.65 <0.0001 1.30 2.99 <0.0001
Major bleeding 2.06 1.65 0.1164 1.60 1.54 0.8063
Minor bleeding 13.79 12.44 0.0349 13.10 12.25 0.1829
Readmission 18.83 12.99 <0.0001 18.34 13.01 <0.0001
VTE, venous thromboembolism.
*All events occurred ≤180 days after discharge.
Table 3 Thromboprophylaxis rates in medically ill patients
Medically ill patient subgroup Patients, N Patients with appropriate prophylaxis
N%
Chronic heart failure 1592 1103 69.3
Thromboembolic stroke 1684 1014 60.2
Severe lung disease 3834 1947 50.8
Acute infection 1658 772 46.6
Cancer 2367 1096 46.3
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Page 5 of 10Table 4 One hundred eighty-day follow-up cost comparison among medically ill patients
Follow-up cost VTE No VTE P-value Major bleeding No major bleeding P-value Minor bleeding No minor bleeding P-value
(n = 296) (n = 10,839) (n = 208) (n = 10,927) (n = 1465) (n = 9670)
Mean Std Mean Std Mean Std Mean Std Mean Std Mean Std
Unadjusted 180-day follow-up cost $52,248 $47,464 $24,038 $63,492 <0.0001 $33,533 $33,432 $24,621 $63,701 0.0003 $33,682 $38,061 $23,440 $66,165 <0.0001
Adjusted 180-day follow-up cost $52,157 $24,389 $24,164 $11,418 <0.0001 $33,656 $18,196 $24,765 $11,974 <0.0001 $33,690 $14,398 $23,610 $11,873 <0.0001
Std, standard difference.
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0that the majority of prescriptions were administered in-
hospital.
Discussion
Using a commercially available hospital drug database
linked with outpatient claims, we evaluated the incidence
of VTE, bleeding events, and associated costs in a cohort
of medically ill patients with available prophylaxis infor-
mation in both in-hospital and outpatient settings. This
analysis extends the findings of previously published
results in medically ill patients, which presented informa-
tion limited to retail pharmacy-dispensed medications
[13].
Recent research suggests that approximately two-thirds
of medical inpatients with risk factors for VTE may receive
some form of thromboprophylaxis and that, typically,
thromboprophylaxis is maintained until hospital discharge,
as is recommended by ACCP guidelines [4], in less than a
quarter of these patients [5]. In a 2004 retrospective study
by Goldhaber and colleagues, only 29% of hospital inpati-
ents had received some form of thromboprophylaxis prior
to their VTE events [6]. The International Medical Preven-
tion Registry on Venous Thromboembolism (IMPROVE)
found that only 6 in 10 eligible medically ill patients
received prophylaxis [14], whereas the Epidemiologic
International Day for the Evaluation of Patients at Risk for
Venous Thromboembolism in the Acute Hospital Care
Setting (ENDORSE) study found that 37% of patients with
cancer or stroke received it [15]. One reason for this lack
of adherence to guidelines may be that in the medically ill,
the focus is necessarily on the patient’s primary diagnosis,
at the expense of VTE prophylaxis. For example, in
patients with acute myocardial infarction (MI), ischemic
cerebrovascular disease, or atrial fibrillation (AF), the pre-
vention of arterial thrombosis is a primary goal and the
prevention of VTE is secondary.
R e s u l t sf r o mt h ec u r r e n ta n a l y s i ss h o w e dt h a td e s p i t e
existing guidelines, almost 47% of patients (n = 5203)
did not receive appropriate anticoagulant prophylaxis,
highlighting the underuse of appropriate anticoagulant
prophylaxis in a wide range of medical inpatients at risk
of VTE in the real world. Although clinical VTE rates
during hospitalization were not evaluated in this analy-
sis, the risk factors studied confirmed that appropriate
anticoagulant prophylaxis use is significantly associated
with an overall reduced risk of clinical VTE, including
events occurring after hospital discharge.
This analysis also demonstrates that appropriate antic-
oagulant prophylaxis use, defined by recommendations
in published guidelines [4], significantly contributes to a
decrease in follow-up total healthcare costs. Indirect
morbidity costs (lost income from work due to the con-
dition or disability), and indirect mortality costs (lost
income due to early mortality) associated with VTE,
which we did not evaluate in this analysis, contribute to
the overall cost of patient care. Therefore, improving
rates of appropriate anticoagulant prophylaxis will
reduce the burden of VTE on the US healthcare system.
There are limitations to our analysis. First, it is based
on retrospective records, which cannot provide full
information on how physicians decide whether to adopt
the prophylaxis practices recommended in current
guidelines. While a determination of appropriate antic-
oagulant use was based on the primary reason for hospi-
tal admission, it is possible that inappropriate
anticoagulant prophylaxis may result from other factors
or a secondary diagnosis. However, the hospital-linked
database was validated and has been used for many ret-
rospective studies.
The next set of limitations is typical of any retrospec-
tive claims database. While claims data are extremely
valuable for treatment patterns, healthcare resource
Table 5 COX model for time to VTE, major bleeding, and minor bleeding events among medically ill patients
Time to VTE Time to major bleeding Time to minor bleeding
Pr > Chi squared Hazard ratio Pr > Chi squared Hazard ratio Pr > Chi squared Hazard ratio
Age, yr 0.9044 1.00 0.8416 1.00 0.1257 1.00
Male 0.4594 0.92 0.0162 1.42 0.1120 1.09
Northeast 0.4015 2.16 0.3896 0.55 0.4711 0.80
North Central 0.3526 1.75 0.0493 0.30 0.0328 0.62
South 0.3603 1.71 0.0583 0.32 0.0647 0.67
Elixhauser Comorbidity Index ≥2 0.3879 1.15 0.5041 0.86 0.8457 1.02
Prior VTE 0.0978 1.30 0.4936 1.28 0.5269 1.09
Chronic heart failure 0.3315 0.83 0.2288 0.74 0.0068 0.79
Thromboembolic stroke 0.0017 0.42 0.3261 1,25 <0.0001 0.64
Severe lung disease 0.8550 1.03 0.5226 0.87 0.0020 0.80
Acute infection 0.7596 1.05 0.2200 0.69 0.0910 0.87
Any anticoagulant <0.0001 0.37 0.8602 1,03 0.5453 0.97
VTE, venous thromboembolism.
Bold font indicates statistical significance.
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Page 7 of 10Table 6 Market share (patient-day based) of anticoagulants used in medically ill patients
Anticoagulant
drug
No. of patients
(%)
Days’ supply per patient
(mean)
Total days’
supply
Days’ supply
per patient
No. of
prescriptions
No. of prescriptions
(inpatient)
No. of prescriptions
(outpatient)
Q1 Median Q3
LMWH 3390 (30.44) 6.30 21,367 2 4 7 17,358 16,865 493
Warfarin 1629 (14.63) 21.49 35,004 2 4 10 8207 7375 832
UFH 3531 (31.71) 5.24 18,508 1 3 6 18,189 15,162 3027
Fondaparinux 42 (0.38) 12.98 545 2 6 9 188 120 68
LMWH, low molecular weight heparin; UFH, unfractionated heparin.
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0utilization, and costs, these data are collected for the
purpose of payment rather than research. The presence
of a diagnosis code on a medical claim is not necessarily
proof of the presence of disease, as diagnoses may be
incorrectly coded or included as rule-out criteria rather
than actual disease. However, we applied detailed quality
checks to the data set before starting the analysis in
order to mitigate these problems. Over-the-counter
medications (e.g. aspirin) and physician-provided sam-
ples were not measurable in the claims data. However,
since our analysis is descriptive and based on evaluating
the effect of anticoagulant prophylaxis on the incidence
and costs of VTE in medically ill patients, we do not
believe this lack of information on over-the-counter
medicine would significantly affect our results.
This analysis suggests that in a large proportion of US
patients diagnosed with an acute medical illness in the
United States, the percentage of those who receive appro-
priate anticoagulant prophylaxis drugs is too low. An
increase in this percentage would likely significantly
decrease VTE rates and total follow-up healthcare costs.
Among possible reasons for the underuse of appropriate
prophylaxis may be a delay in adopting clinical practice
guidelines by physicians, who often view guidelines as dif-
ficult to apply [15]. Physicians’ attitudes, fears about
increased risk of bleeding, and adherence problems result-
ing from limitations of current therapies might also contri-
bute to this lack of prophylaxis use [14].
Conclusions
Appropriate anticoagulant prophylaxis results in lower
VTE event rates and total follow-up healthcare costs in
medically ill patients. However, in real-world populations
in the United States, adherence to guideline-recommended
anticoagulant prophylaxis in patients diagnosed with an
acute medical illness is low.
Appendix
ICD-9-CM codes used to define medical conditions
1. Chronic heart failure: 398.9x, 402.01, 402.11,
402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, 425.4x, 428.xx
2. Thromboembolic stroke: 433.xx, 434.xx, 435.xx,
436.xx
3. Severe lung disease: 466.xx, 480.xx, 481.xx, 482.
xx, 483.xx, 484.xx, 485.xx, 486.xx, 487.xx, 490.xx,
491.xx, 492.xx, 493.xx, 494.xx, 495.xx, 496.xx, 500.xx,
501.xx, 502.xx, 503.xx, 504.xx, 510.xx, 511.xx, 512.xx,
513.0x, 514.xx, 515.xx, 516.xx, 518.0x, 518.2x, 518.3x,
518.4x, 518.5x, 518.81, 518.82, 518.83, 518.84,
518.89, 136.3
4. Acute infection: 003.1x, 008.xx, 020.2x, 022.3x,
027.xx, 036.2x, 038.xx, 041.xx, 054.5x, 098.89, 112.
xx, 376.01, 478.21, 478.71, 528.3, 590.xx, 595.xx, 597.
xx, 614.4, 681.xx, 682.xx, 790.7x
5. Cancer: 140.xx - 208.xx, 230.xx - 234.xx
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